S. Peter Wu, M.D.

Radiation oncologist S. Peter Wu, M.D., was inspired to become a physician by the example of his mother, who was a pediatric surgeon in her native China. After the family came to America, he watched as a child while she put in many years of hard work to obtain her stateside license as a doctor.

Today, Dr. Wu continues her legacy by providing patients with the same quality of care that he would want for himself or a family member. He joined City of Hope in 2023, having co-authored over two dozen peer-reviewed scientific studies spanning basic mechanisms in cancer and its treatment, clinical trials of new therapies and cancer epidemiology. He also has a particular special interest in radiotherapy for breast cancer patients. Before City of Hope, Dr. Wu worked at Holy Name Medical Center in New Jersey.

An immigrant from China who has lived in five states and trained in New York City, Dr. Wu loves serving patients of all backgrounds, ethnicities, genders and belief systems. He is a proud husband and father of two young children.

Awards

• 2017, ASCO Annual Meeting 2017 Conquer Cancer Foundation Merit Award
• 2013, Track Team Player Award, University of Michigan Medical School
• 2011, Commendation for Caring Service, University of Michigan Medical School
• 2010, Oren Hyman Scholar (1/2 Tuition), University of Michigan Medical School
• 2008, William H. Cane Scholarship (1/2 Tuition), Princeton University

Publications

• Wang H, Cooper BT, Schiff P, Sanfilippo NJ, Wu SP, Hu KS, Das IJ, Xue J. Dosimetric assessment of tumor control probability in intensity and volumetric modulated radiotherapy plans. The British Journal of Radiology. 2019;92(1094), p.20180471.
• Katz LM, Hielscher T, Liechty B, Silverman J, Zagzag D, Sen R, Wu P, Golfinos JG, Reuss D, Neidert MC, Wisching HG, Baumgarten P, Herold-Mende C, Wick W, Harter PN, Weller M, von Deimling A, Snuderl M, Sen C, Sahm F. Loss of histone H3K27me3 identifies a subset of meningiomas with increased risk of recurrence. Acta neuropathol. 2018 Jun;135(6):955-963.
• Wu SP, Cooper BT, Bu F, Bowman CJ, Killian JK, Serrano J, Wang S, Jackson TM, Gorovets D, Shukla N, Meyers P, Pisapia D, Gorlick R, Ladanyi M, Thomas K, Snuderl M, Karajannis M. DNA methylation-based classifier for accurate molecular diagnosis of bone sarcomas. JCO Precis Oncol. 2017;1:1-11.
• Wu SP, Pfeiffer RM, Ahn I, Mailankody S, Sonneveld P, van Duin M, Munshi NC, Walker BA, Morgan G, Landgren O. Impact of genes highly correlated with MMSET myeloma on survival of Non-MMSET myeloma patients. Clin Cancer Res. 2016 Aug 15;22(16):4039-44.
• Kwok M, Wu SP, Mo C, Summers T, Roschewski M. Circulating tumor DNA to monitor therapy for aggressive B- cell lymphomas. Curr Treat Options Oncol. 2016;17(9):47.
• Hassler JR, Scheuner DL, Wang S, Han J, Kodali VK, Li P, Nguyen J, George JS, Davis C, Wu SP, Bai Y, Sartor M, Cavalcoli J, Malhi H, Baudouin G, Zhang Y, Yates JR III, Itkin-Ansari P, Volkmann N, Kaufman RJ. The IRE1α/XBP1s pathway is essential for the glucose response and protection of β cells. PLoS Biol. 2015 Oct 15;13(10):e1002277.
• Zingone A, Wang W, Corrigan-Cummins M, Wu SP, Plyler R, Korde N, Kwok M, Manasanch EE, Tageja N, Bhutani M, Mulquin M, Zuchlinski D, Yancey MA, Roschewski M, Zhang Y, Roccaro AM, Ghobrial IM, Calvo KR, Landgren O. Altered cytokine and chemokine profiles in multiple myeloma and its precursor disease. Cytokine. 2014;69(2):294-7.
• Wu S, Langlotz CP, Lakhani P, Ungar LH. Extracting templates from radiology reports using sequence alignment. Int J Data Min Bioinform. 2012;6(6):633-50.